Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Go online to PeerView.com/KQX860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. The use of asparaginase, including E coli- and
Erwinia-derived compounds, remains an important component of
pediatric acute lymphoblastic leukemia (ALL) care, and its use has
consistently improved survival outcomes—are you up to the challenge
of developing modern regimens that ensure appropriate exposure to
asparaginase? In this PeerView CME activity, based on a live
“Clinical Consults” symposium at the 2022 ASPHO conference, Drs.
Stuart S. Winter and Reuven Schore address the challenges of
clinical decision-making with asparaginase compounds as part of
pediatric ALL therapy, focusing on topics such as the management of
E coli-derived asparaginase hypersensitivity or silent
inactivation, preventing discontinuation/truncation, and the
integration of novel Erwinia formulations when E coli-derived
asparaginase discontinuation occurs. Tune in to learn how to adapt
your practice to reflect the innovative science supporting the use
of modern asparaginase compounds in pediatric ALL. Upon completion
of this activity, participants should be better able to: Describe
the clinical ramifications of Escherichia coli asparaginase
hypersensitivity and asparaginase discontinuation in pediatric
acute lymphoblastic leukemia (ALL), Cite efficacy and safety
evidence surrounding the use of Erwinia chrysanthemi asparaginase,
including recombinant formulations as a component of multi-agent
chemotherapy for pediatric ALL, Implement strategies to overcome
barriers to the effective use of asparaginase in pediatric ALL,
including the use of appropriate monitoring and management for
hypersensitivity, mitigation for infusion reactions, and the
integration of novel Erwinia asparaginase compounds into treatment
plans.